ENXTPA:IPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Innate Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IPH is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IPH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

4.6%

IPH

0.4%

FR Biotechs

0.4%

FR Market


1 Year Return

-24.7%

IPH

27.7%

FR Biotechs

-3.0%

FR Market

Return vs Industry: IPH underperformed the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: IPH underperformed the French Market which returned -3% over the past year.


Shareholder returns

IPHIndustryMarket
7 Day4.6%0.4%0.4%
30 Day30.0%7.8%13.2%
90 Day-17.8%18.5%11.0%
1 Year-24.7%-24.7%27.8%27.7%-1.0%-3.0%
3 Year-11.6%-11.6%-35.9%-36.0%16.6%6.9%
5 Year-69.5%-69.5%-66.0%-66.2%44.5%24.8%

Long-Term Price Volatility Vs. Market

How volatile is Innate Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innate Pharma undervalued compared to its fair value and its price relative to the market?

1.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IPH is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: IPH is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPH is good value based on its PB Ratio (1.7x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Innate Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

6.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPH's revenue (3.1% per year) is forecast to grow slower than the French market (7.3% per year).

High Growth Revenue: IPH's revenue (3.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IPH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Innate Pharma performed over the past 5 years?

-10.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPH is currently unprofitable.

Growing Profit Margin: IPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPH is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare IPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: IPH has a negative Return on Equity (-21.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Innate Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: IPH's short term assets (€163.7M) exceed its short term liabilities (€82.3M).

Long Term Liabilities: IPH's short term assets (€163.7M) exceed its long term liabilities (€43.0M).


Debt to Equity History and Analysis

Debt Level: IPH's debt to equity ratio (7.2%) is considered satisfactory.

Reducing Debt: IPH's debt to equity ratio has increased from 2.2% to 7.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IPH has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 38.7% each year.


Next Steps

Dividend

What is Innate Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IPH's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Mondher Mahjoubi (62 yo)

3.92yrs

Tenure

€1,390,923

Compensation

Dr. Mondher Mahjoubi, M.D., serves as Chairman at PDC line Pharma SAS since June 2020. He has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016....


CEO Compensation Analysis

Compensation vs Market: Mondher's total compensation ($USD1.66M) is above average for companies of similar size in the French market ($USD548.13K).

Compensation vs Earnings: Mondher's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mondher Mahjoubi
Chairman of Executive Board & CEO3.92yrs€1.39m0.38%
€ 1.3m
Laure-Hélène Mercier
Executive VP3.92yrs€545.11k0.081%
€ 278.5k
Yannis Morel
Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board5.5yrs€571.74k0.083%
€ 287.4k
Hervé Brailly
Co-Founder & Chairman of Supervisory Board3.92yrs€150.00k1.24%
€ 4.3m
François Romagné
no datano datano data
Eric Vivier
Founderno datano data0.092%
€ 316.8k
Marc Bonneville
no datano datano data
Jean Fournié
no datano datano data
Alessandro Moretta
no datano datano data
Danielle Spangler
Head of Investor Relationsno datano datano data
Odile Belzunce
Vice President of Compliance1.83yrsno data0.0067%
€ 23.0k
Tracy Rossin
VP & Global Head of Communications1.17yrsno datano data

3.9yrs

Average Tenure

56yo

Average Age

Experienced Management: IPH's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hervé Brailly
Co-Founder & Chairman of Supervisory Board3.92yrs€150.00k1.24%
€ 4.3m
Patrick Langlois
Independent Member of Supervisory Board10.5yrs€48.55k0.010%
€ 35.5k
Ruslan Medzhitov
Strategic Advisory Board Member2yrsno datano data
Mailys Ferrere
Member of Supervisory Board3.42yrsno datano data
Gilles Brisson
Independent Member of Supervisory Board13.33yrs€42.60k0.061%
€ 209.5k
Jean-Yves Blay
Independent Member of Supervisory Board2.92yrs€24.00k0.000060%
€ 206.6
Irina Staatz-Granzer
Independent Vice Chairman of Supervisory Boardno data€27.55k0.032%
€ 109.4k
Miriam Merad
Chairman of Strategic Advisory Boardno datano datano data
Véronique Chabernaud
Independent Member of Supervisory Board5.58yrs€32.30k0.000010%
€ 34.4
Sebastian Amigorena
Strategic Advisory Board Member2yrsno datano data
Marcus Schindler
Member of Supervisory Board2.67yrsno datano data
Aurelien Marabelle
Strategic Advisory Board Member2yrsno datano data

3.2yrs

Average Tenure

59yo

Average Age

Experienced Board: IPH's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innate Pharma S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innate Pharma S.A.
  • Ticker: IPH
  • Exchange: ENXTPA
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €344.277m
  • Shares outstanding: 78.96m
  • Website: https://www.innate-pharma.com

Number of Employees


Location

  • Innate Pharma S.A.
  • 117 Avenue de Luminy
  • BP 30191
  • Marseille
  • Provence-Alpes-Côte d'Azur
  • 13009
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPHENXTPA (Euronext Paris)YesCategory O Ordinary SharesFREURNov 2006
IDDDB (Deutsche Boerse AG)YesCategory O Ordinary SharesDEEURNov 2006
0EVILSE (London Stock Exchange)YesCategory O Ordinary SharesGBEURNov 2006
IPHY.FOTCPK (Pink Sheets LLC)YesCategory O Ordinary SharesUSUSDNov 2006
IPHPBATS-CHIXE (BATS 'Chi-X Europe')YesCategory O Ordinary SharesGBEURNov 2006
IPHSWX (SIX Swiss Exchange)YesCategory O Ordinary SharesCHCHFNov 2006
IPHANasdaqGM (Nasdaq Global Market)UNSPONSORD ADSUSUSDOct 2015
IDDBMUN (Boerse Muenchen)UNSPONSORD ADSDEEUROct 2015
IPHANasdaqGS (Nasdaq Global Select)SPONSORED ADSUSUSDOct 2019
IDDAMUN (Boerse Muenchen)SPONSORED ADSDEEUROct 2019

Biography

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company’s products include Monalizuma...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 18:50
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.